Erythropoietin modulates imbalance of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in doxorubicin-induced cardiotoxicity.

@article{Chen2014ErythropoietinMI,
  title={Erythropoietin modulates imbalance of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in doxorubicin-induced cardiotoxicity.},
  author={Xing Chen and Zhihua Guo and Peixian Wang and Miqing Xu},
  journal={Heart, lung & circulation},
  year={2014},
  volume={23 8},
  pages={
          772-7
        }
}
BACKGROUND Doxorubicin (DOX) is a highly effective anti-cancer drug with limited clinical use due to its serious cardiotoxicity. Recent studies reported that erythropoietin (EPO) could exert a cardioprotective effect by non-erythropoietic effects. This study was to investigate fibrosis of DOX-induced cardiotoxicity and determine mechanisms of EPO against extracellular matrix (ECM) remodelling. METHODS Rats were grouped as the control group, the DOX group and the DOX+EPO group. DOX (2.5 mg/kg… CONTINUE READING